Multicenter study demonstrates specimen PET-CT provides actionable information at the point of decision-making, improving identification and management of positive margins during breast-conserving surgery featuring XEOS
GHENT, BELGIUM, June 18, 2026 — XEOS, a medical technology company advancing intraoperative molecular imaging, today announced the publication of the BrIMA (Breast cancer Intraoperative Margin Assessment) study in JAMA Surgery, world’s leading peer reviewed surgical journals. The prospective, multicenter clinical trial demonstrated that the specimen images obtained with the AURA 10® PET-CT system significantly improved surgeons’ ability to identify and address positive margins during breast-conserving surgery, providing actionable information at the point where surgical decisions are made.
As the largest prospective multicenter evaluation of specimen PET-CT for intraoperative margin assessment in breast-conserving surgery conducted to date, BrIMA provides important new evidence supporting the role of intraoperative molecular imaging in surgical decision-making.
